Condition
IrAE
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (2)
P 4 (1)
Trial Status
Recruiting2
Unknown1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07381634Phase 2Recruiting
The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
NCT06461780Recruiting
Exploring Physical and Psychological Needs and Quality of Life in Patients With Advanced Cancer Receiving Immunotherapy
NCT07303881Phase 2Not Yet RecruitingPrimary
Golidocitinib for Refractory Immune-related Hematologic Toxicities of Advanced Lung Cancer
NCT06178146Phase 4UnknownPrimary
Thymosin Alpha-1 for irAE Secondary to ICIs
Showing all 4 trials